Does UnitedHealthcare Cover Metformin?

How UnitedHealthcare Places Metformin on Its Formulary

Generic immediate-release metformin sits at Tier 1 or Tier 2 on the vast majority of UnitedHealthcare commercial formularies, meaning most members pay $0, $10 per 30-day supply with no prior authorization required. The branded extended-release tablet (Glucophage XR) typically lands at Tier 3 or Tier 4, where a PA is more likely. FDA prescribing information for metformin hydrochloride confirms the drug's long-standing approval for type 2 diabetes in adults and children aged 10 and older. [1]

UHC publishes its plan-specific formularies through the UHC Drug List search tool, and the tier assignment for your specific policy depends on whether you hold an employer-sponsored PPO, HMO, individual Marketplace plan, Medicare Advantage plan, or Medicaid (UHC Community Plan) policy. Always verify the tier against your Summary of Benefits before filling a new prescription.

Generic metformin 500 mg, 850 mg, and 1 to 000 mg tablets are all listed on the UHC Core Formulary. Extended-release versions (500 mg ER, 750 mg ER) vary by plan. Liquid metformin (Riomet) is typically Tier 3 across commercial products. [2]

The American Diabetes Association's 2024 Standards of Care designate metformin as a first-line pharmacological agent for type 2 diabetes when lifestyle changes alone do not achieve glycemic targets, a recommendation that directly supports coverage under most plans. [2]

Prior Authorization for Metformin on UnitedHealthcare

Prior authorization is not required for generic immediate-release metformin prescribed for type 2 diabetes on most UHC commercial and Medicare Advantage plans. PA is more commonly required in three specific situations: (1) the prescriber orders branded Glucophage XR and the plan's step-therapy rule has not been satisfied, (2) the diagnosis code on the prescription is for an off-label use such as polycystic ovary syndrome (PCOS) or prediabetes prevention, or (3) the member's plan is a narrow-network HMO with tighter utilization management.

When a PA is required, UHC uses its standard clinical prior-authorization form. The prescriber must document the diagnosis (ICD-10 E11.x for type 2 diabetes), the HbA1c value, any contraindications to the preferred alternative, and the clinical rationale. According to UHC's published utilization-management criteria, PA decisions for preferred generics are generally returned within 72 hours for standard requests and 24 hours for urgent requests. [3]

The 1998 UKPDS 34 trial (N=1,704 overweight patients with newly diagnosed type 2 diabetes) published in The Lancet demonstrated that intensive metformin therapy reduced all-cause mortality by 36% and diabetes-related endpoints by 32% compared with diet alone, evidence that forms the clinical backbone of every coverage defense for this drug. [4] That level of outcomes data makes denials on clinical grounds rare for the approved indication.

For PCOS, prediabetes, or weight management use, PA requirements are stricter. The prescriber must supply supporting lab work (fasting glucose, HbA1c, lipid panel) and document that lifestyle modification was attempted for at least 3 months. [3]

Step Therapy Rules: What UHC Requires Before Branded Metformin

Step therapy applies almost exclusively to branded extended-release formulations, not to generic metformin. UHC's standard step-therapy protocol for branded ER products requires a documented 30-day trial of generic immediate-release metformin (or a clinical reason why the IR formulation is not tolerated, such as persistent GI adverse effects at the maximum tolerated dose). [5]

Generic IR metformin carries an FDA black-box warning regarding lactic acidosis risk in patients with renal impairment (eGFR <30 mL/min/1.73m²), which is one legitimate clinical basis for skipping the IR step and going directly to ER. [1] ER formulations produce lower peak plasma concentrations, reducing the incidence of nausea and diarrhea by roughly 50% compared with IR at equivalent daily doses, according to a pharmacokinetic review published in Diabetes Care. [6]

If your prescriber documents intolerance to IR metformin, UHC will generally waive the step-therapy requirement and approve the ER product at whatever tier it occupies on your plan. The documentation needs to be explicit: a chart note stating the patient experienced grade 2 or higher GI toxicity at doses at or below 1 to 000 mg/day is typically sufficient. [5]

What Metformin Costs on UnitedHealthcare vs. Cash Pay

Cost matters. Here is what members actually pay across different coverage scenarios.

With UHC insurance (generic IR): Most commercial members pay $0, $10 per 30-day supply at a preferred-network pharmacy. Medicare Advantage members with Low Income Subsidy (LIS/Extra Help) pay $0, $3.95 per fill under the 2024 benchmark. [7]

With UHC insurance (branded Glucophage XR): Tier 3 copays typically run $40, $60 per 30-day fill on commercial plans and $42, $47 under most Part D plans without LIS. [7]

Cash pay (no insurance): GoodRx benchmarks generic metformin 500 mg, 60 tablets at approximately $8 per month at major chains including CVS, Walgreens, and Walmart. The $4 generic programs at Walmart and Kroger pharmacy can reduce this further.

Manufacturer savings cards: Novo Nordisk, AstraZeneca, and other branded pharmaceutical companies offer savings cards, but these cards cannot be used alongside federal insurance programs including Medicare Part D or Medicaid. They are valid only for commercially insured patients or cash-pay patients. Applying a manufacturer savings card when enrolled in a federal program is a federal anti-kickback violation under 42 U.S.C. § 1320a-7b(b). [8]

The CDC estimates that 37.3 million Americans, 11.3% of the U.S. population, had diagnosed or undiagnosed diabetes as of 2022. [9] Generic metformin's near-zero cost relative to newer agents (semaglutide oral $900/month list, empagliflozin $600/month list) keeps it the default first-line choice on almost every insurer's preferred drug list.

Metformin for Weight Loss: Does UHC Cover Off-Label Use?

Metformin is not FDA-approved for weight loss, and UHC does not list weight loss as a covered indication. Coverage for an off-label weight-management use depends on your specific plan language and the presence of a comorbid condition that gives the prescriber a defensible on-label basis (most commonly type 2 diabetes or PCOS with metabolic features). [10]

The Diabetes Prevention Program Outcomes Study (DPPOS), which followed 3,234 high-risk adults over 15 years, showed that metformin 850 mg twice daily reduced progression from prediabetes to type 2 diabetes by 18% compared with placebo at the 15-year mark. [10] That long-term data supports some plans covering metformin for prediabetes with the appropriate ICD-10 code R73.09 (prediabetes) or Z83.3 (family history of diabetes). Check your Summary of Benefits or call UHC Member Services at 1-866-801-4409 to verify.

The table below summarizes the coverage decision logic a UHC clinical reviewer typically follows:

| Clinical Scenario | Covered? | PA Required? | |---|---|---| | Type 2 diabetes, generic IR | Yes | No | | Type 2 diabetes, branded ER | Yes (after step therapy) | Usually yes | | Prediabetes (R73.09), generic IR | Plan-dependent | Often yes | | PCOS (E28.2), generic IR | Plan-dependent | Often yes | | Weight loss only, no comorbidity | No | N/A | | Pediatric type 2 diabetes (age 10+) | Yes | No |

How to Appeal a UnitedHealthcare Denial of Metformin

UHC uses a two-level internal appeal process followed by external review if both internal levels fail. Each step has federally mandated timelines under the ACA and ERISA.

Step 1: Level 1 Internal Appeal. File within 180 days of the denial notice. UHC must respond within 30 days for prospective (pre-service) appeals and 60 days for retrospective (post-service) denials. For urgent concurrent care, the timeline compresses to 72 hours. Submit your appeal in writing to the address on your Explanation of Benefits, and include: a letter of medical necessity from your prescriber, supporting lab values (HbA1c, eGFR, fasting glucose), the relevant published guideline (ADA 2024 Standards of Care), and UKPDS 34 as a clinical reference. [4]

Step 2: Level 2 Internal Appeal. If Level 1 is denied, you have 60 days to escalate. A different UHC clinical reviewer (not involved in the Level 1 decision) must respond within 30 days. [11]

Step 3: External Independent Review Organization (IRO). If both internal levels are denied, federal law (ACA Section 2719) mandates access to an independent external review. UHC must submit your file to a state-certified IRO within 5 business days of your request. The IRO's decision is binding on UHC. IRO decisions favor the member in approximately 39 to 45% of drug coverage disputes, according to a 2019 analysis published in Health Affairs. [11]

Step 4: State Insurance Commissioner complaint. If you are on a fully insured plan (not self-funded ERISA), you can simultaneously file a complaint with your state insurance department. Self-funded ERISA plans are regulated federally, so complaints go to the U.S. Department of Labor Employee Benefits Security Administration (EBSA). [12]

Practical tips that strengthen an appeal:

• Get your prescriber to use the phrase "medically necessary" explicitly in the letter. UHC's internal criteria define medical necessity as care that is "consistent with generally accepted standards of medical practice", language that maps directly to ADA guidelines.
• Reference the specific UHC coverage policy number that was cited in the denial letter. Arguing against the actual policy text is more persuasive than a general medical necessity argument.
• Include the UKPDS 34 mortality-reduction data. [4] Clinical reviewers respond to hard endpoint trial data.
• If your plan is a Medicare Advantage plan, note that CMS requires formulary exceptions for non-covered drugs when a plan-covered alternative is contraindicated or causes an adverse effect. [7]

Metformin Dosing, Safety, and Monitoring Relevant to Coverage

Understanding dosing helps you and your prescriber frame coverage requests correctly. Metformin is started at 500 mg once or twice daily with meals and titrated over 2 to 4 weeks to a target of 1,500, 2 to 000 mg/day in two divided doses for IR, or up to 2 to 000 mg once daily for ER. [1]

Renal function monitoring is mandatory. The FDA updated prescribing information in 2016 to allow metformin use when eGFR is 30 to 45 mL/min/1.73m² with increased monitoring frequency, and to contraindicate use below eGFR <30 mL/min/1.73m². [1] A 2020 Cochrane review (27 trials, N=2,166) found no cases of fatal lactic acidosis among metformin users compared with non-users in controlled settings, challenging the historical severity of this warning. [13]

Vitamin B12 deficiency is an underappreciated long-term effect. The DPPOS reported that 30% of long-term metformin users had biochemical B12 deficiency after 13 years of treatment, compared with 8.9% of placebo users (P<0.001). [14] UHC covers B12 testing (CPT 82607) under most preventive or diagnostic lab benefits when ordered alongside metformin monitoring.

Drug interactions most relevant to coverage appeals: contrast media (hold metformin 48 hours before iodinated contrast if eGFR <60 mL/min/1.73m²), carbonic anhydrase inhibitors (topiramate, acetazolamide increase lactic acidosis risk), and alcohol in large amounts. [1]

Medicare Advantage and Medicaid Coverage Specifics

Medicare Advantage (Part D): Generic metformin is on the CMS Low-Income Subsidy benchmark formulary, meaning all Medicare Advantage Part D plans must cover it. Members with Extra Help pay $0, $3.95 per fill in 2024. Without Extra Help, Tier 1 generic copays on Medicare Advantage Part D plans run $0, $7 for a 30-day supply and $0, $14 for a 90-day mail-order supply. [7]

CMS requires that Part D plans include metformin on their formulary as it is a protected class equivalent for diabetes. A plan cannot simply drop metformin from coverage mid-year without CMS approval.

Medicaid (UHC Community Plan): All 50 state Medicaid programs cover metformin. Under UHC Community Plan (Medicaid managed care), generic metformin is Tier 1 with $0 or nominal $1, $3 copay. PA is not required for type 2 diabetes. Prediabetes coverage varies by state Medicaid policy.

ACA Marketplace (UHC Choice / Manage plans): Generic metformin is covered under essential health benefits as a prescription drug. The Affordable Care Act requires plans to provide coverage for the 150+ generic drugs on the HRSA preventive services list, and metformin for diabetes prevention appears on the USPSTF B-rated recommendation list for prediabetes. [15]

How to Check Your Specific UHC Plan's Metformin Coverage

Coverage details differ by plan ID. Four direct methods to verify yours:

1. Log into myuhc.com, select "Prescriptions," and search "metformin" in the formulary tool. The result shows tier, copay, and any PA or step-therapy flag.
2. Call UHC Member Services (number on your insurance card or 1-866-801-4409 for commercial plans).
3. Ask your pharmacist to run a test claim before filling. A test claim reveals the exact copay and any PA requirement in real time without dispensing the drug.
4. Request your plan's Evidence of Coverage document, which lists all PA criteria in the pharmacy benefit section.

If the formulary tool shows a PA requirement, ask your prescriber's office to use UHC's electronic prior-authorization portal (UHC Provider Portal) rather than fax-based PA, as electronic submissions average 48-hour turnaround versus 5, 7 business days for fax. [3]

The ADA's 2024 Standards of Care (Section 9: Pharmacologic Approaches to Glycemic Treatment) state: "Metformin remains an effective, safe, and low-cost medication and should be the preferred initial pharmacologic agent for type 2 diabetes." [2] That direct guideline language is your strongest single argument in any coverage dispute.